Xarelto Lawsuit Claiming Wrongful Death Filed By South Florida Resident After Husband’s Fatal Bleeding Episode

April 07, 2016 – – BloodThinnerHelp.com reports on the details of another lawsuit filed against Bayer and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation). The plaintiff filing is a widow who alleges that the new-generation, blood-thinning drug Xarelto that they manufacture caused the premature bleeding death of her husband. Her lawsuit was later transferred to the Eastern District of Louisiana to join thousands of others consolidated to form multidistrict litigation No. 2592.

The widow’s complaint was initially filed in Southern Florida under case number 9:14-cv-80831. She alleges that Bayer and Janssen acted with negligence by not effectively warning consumers and medical professionals about the potential dangers of their product. She claims that Xarelto caused her husband’s death, as he was using it to prevent a stroke due to his atrial fibrillation condition. While using it, however, he suddenly suffered from a brain bleed known as a subdural hemorrhage. Because he had the blood thinner in his system at the time of the bleed, doctors were unable to stop it or clot his blood. The man died after losing too much blood.

Just five years ago in 2011, the U.S. Food and Drug Administration approved Xarelto and the anticoagulant launched onto the market as a revolutionary new type of blood thinner. It was popular and provided patients with freedoms that traditional blood thinners had been unable to. Today, patients ask–at what cost? Since it’s launch, the drug has been the recipient of two “black box” warnings from the FDA. These are the most strict warnings a product can receive before being fully removed from the market.

For years as well, the product was on the market and used among patients without any corresponding antidote. Traditional blood thinners have an available antidote in vitamin K, so if patients taking them suffer an injury and begin to bleed, physicians have the option of treating them with vitamin K to counteract the blood thinner’s effects and clot their blood. Xarelto patients did not have this option for a number of years. Many plaintiffs who suffered bleeds while the product had no available antidote allege that the manufacturers acted with dangerous negligence by releasing it to market this way.

Xarelto has now become the subject of over 3,400 lawsuits filed by plaintiffs from across the United States. 2,800 of these lawsuits were federally-filed and have been consolidated to form MDL number 2592 in Eastern Louisiana. More than 620 others, however, have been formed into a mass tort program by the Court of Common Pleas in Philadelphia, Pennsylvania.

Attorney Joseph Osborne is currently working to assist other patients who have used Xarelto and feel that the drug caused them to suffer from health complications. Affected patients could be entitled to significant compensation, and deserve the opportunity to explore their legal rights in the matter. To better help those interested in investigating their options, Attorney Joseph Osborne is currently offering free legal consultations for qualified parties.

To request additional Xarelto bleeding lawsuit information, or to ask questions, contact Joseph Osborne, Esq. by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60009163